| Deal value | $200M |
|---|---|
| Share of market cap | 10.0% |
Key highlights
- Public offering of 61,540,000 shares of Class A common stock priced at $3.25 per share
- Expected gross proceeds of $200 million to fund operations through 2029
- Sanofi exercised an option for a dual-targeting immunology candidate, triggering a $10 million payment
- Total payments received from the Sanofi collaboration now reach $144 million
- Preliminary cash and equivalents reported at $561 million as of September 30, 2026
Details of the Offering
Recursion Pharmaceuticals entered into an underwriting agreement with a syndicate led by Leerink Partners, Goldman Sachs, Morgan Stanley, and Evercore for the sale of 61,540,000 shares. The offering is priced at $3.25 per share, representing a transaction focused on strengthening the balance sheet for long-term clinical development. The company anticipates closing the offering on October 16, 2026. In conjunction with the raise, executive officers and directors have entered into 45-day lock-up agreements, which restrict the immediate sale of additional shares to maintain market stability following the capital infusion.
Financial Position and Cash Runway
- Projected cash runway extended into 2029 following the completion of the $200 million equity raise
- Preliminary cash balance of $561 million includes $86 million in net proceeds from Q3 ATM program sales
- Full-year 2026 cash operating expenses are guided to remain below $375 million
- Over $20 billion in total potential milestone payments identified across various partner portfolios
- Current offering proceeds will support iterative cycles of chemical design and experimental validation
Sanofi Collaboration Milestone
The company also announced that Sanofi has optioned the first development candidate from their multi-program research partnership. This triggers a $10 million milestone payment, bringing the total upfront and milestone payments from Sanofi to $144 million to date. The candidate is a potential first-in-class oral small molecule designed for dual-targeting in inflammatory diseases. Sanofi will now lead further development, including a Phase 1 clinical study planned for 2027. Recursion remains eligible for over $300 million in additional milestones and double-digit royalties on future net product sales if the candidate reaches commercialization.
Strategic Rationale
“The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines. Together with Sanofi, we tackled a difficult design problem against a dual target product profile with high potential and delivered a molecule that Sanofi has now selected for its development pipeline.”
| Date | Announcement | Amount |
|---|---|---|
| 24 Feb 2026 | At-the-market equity offering sales agreementSource: SEC filing | $300.0 Million |
| 08 Jul 2025 | Private placement of Class A common stockSource: SEC filing | $7.5 Million |
| 28 Feb 2025 | At-the-market equity offering sales agreementSource: companiesmarketcap.com | $500.0 Million |
Management commentary
“The most important test of any technology platform in drug discovery is whether it can translate into differentiated medicines.”
“By combining Sanofi's drug discovery and clinical and translational knowledge in Immunology with Recursion's AI-driven platform, we were able to move with speed and precision in a space where that balance is notoriously hard to achieve.”
| Share price | $3.74 |
|---|---|
| Market cap | $2.0B |
| Revenue (annual) | $74M |
| 1-month price change | +9.68% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Recursion Pharmaceuticals announcing a $200 million underwriting agreement and a $10 million milestone payment from Sanofi.
Track RECURSION PHARMACEUTICALS, INC. live
Get the next RECURSION PHARMACEUTICALS, INC. SEC filing seconds after it lands.
